What is the 13F Pro Quality Score for BTMD?

13F Pro ranks biote Corp. (BTMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BTMD's current score at https://13fpro.ai/research/BTMD (free sign-up required for the full ranking).

Which hedge funds own the most BTMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BTMD include 325 CAPITAL, Bandera Partners, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BTMD as soon as new 13F filings post.

Where does 13F Pro source BTMD data?

All biote Corp. fundamentals and ownership data come directly from SEC EDGAR. biote Corp. files with the SEC under CIK 1819253. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BTMD in?

biote Corp. (BTMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BTMD research updated on 13F Pro?

BTMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

biote Corp.(BTMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1819253 BTMD stock profile & AI dashboard →

13F Pro Quality Score

56.6/100

Rank #1,089 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

36.3/100

Profitability

82.5/100

Balance Sheet

98.2/100

Earnings Quality

30.0/100

Free Cash Flow

71.7/100

Institutional Flow

17.6/100

Revenue Scale

23.8/100

Dilution Risk

27.0/100

BTMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for biote Corp. (BTMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BTMD at 56.6/100 on a 32-signal composite quality model, placing it at rank #1,089 of 2,879 stocks — the top half of the AI-ranked universe. BTMD scores in the top quartile across balance sheet strength (98.2), profitability (82.5). Areas of concern include institutional flow (17.6) and revenue scale (23.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 27.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), biote Corp. reports quarterly revenue of $44.9M, net income of $2.3M, free cash flow of $3.5M. Top institutional holders of BTMD by reported 13-F value include 325 CAPITAL, Bandera Partners, BlackRock,, based on the most recent SEC filings. BTMD trades on the Nasdaq exchange and files with the SEC under CIK 1819253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for biote Corp. directly from SEC EDGAR. biote Corp.'s 13F Pro composite quality score has ranged between 8 and 63 since 2023, currently 56.6 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about biote Corp.

Quirks, history, and lore behind BTMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Texas.
2
The Numbers
The company has trained a network of thousands of certified physician practices across the U.S., making its revenue model lean heavily on licensing and training fees rather than direct patient care.
3
The History
Founded in the 2010s, it went public via a SPAC merger — perfectly on-trend for its era — and built its business around a medical niche that baby boomers care about a lot.
4
The Secret
Its entire platform is built around hormone optimization therapy — specifically pellet-based bioidentical hormone replacement administered by trained clinicians.
5
The Lore
The company essentially franchises a clinical protocol: it certifies doctors, supplies the pellets, and handles the back-office — turning hormone therapy into a repeatable, scalable business.
6
The Giveaway
Its name is a mashup of "bio" and a suffix that sounds like a treatment — a testosterone and estrogen pellet therapy company that has quietly built one of the largest hormone optimization networks in America.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$44.9M

Net Income

Q1 2026

$2.3M

Free Cash Flow

Q1 2026

$3.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+12.4% YoY

$185.4MFY 2023

FY21 $139.4MFY22 $165.0MFY23 $185.4M

Net Income

+442.2% YoY

$3.3MFY 2023

FY21 $11.1MFY22 $-969.0KFY23 $3.3M

Operating Income

+147.2% YoY

$28.7MFY 2023

FY21 $34.6MFY22 $-60.7MFY23 $28.7M

EPS (Diluted)

+208.3% YoY

$0.13FY 2023

FY21 —FY22 $-0.12FY23 $0.13

Total Assets

+39.1% YoY

$155.3MFY 2023

FY21 $54.3MFY22 $111.6MFY23 $155.3M

Total Debt

-4.9% YoY

$121.9MFY 2023

FY21 $37.0MFY22 $128.1MFY23 $121.9M

Op. Cash Flow

+393.6% YoY

$26.9MFY 2023

FY21 $33.7MFY22 $-9.2MFY23 $26.9M

Metric	FY 2023	FY 2022	FY 2021
Revenue	$185.4M +12.4%	$165.0M +18.3%	$139.4M
Net Income	$3.3M +442.2%	$-969.0K -108.7%	$11.1M
Operating Income	$28.7M +147.2%	$-60.7M -275.7%	$34.6M
EPS (Diluted)	$0.13 +208.3%	$-0.12	—
Total Assets	$155.3M +39.1%	$111.6M +105.5%	$54.3M
Total Debt	$121.9M -4.9%	$128.1M +246.6%	$37.0M
Operating Cash Flow	$26.9M +393.6%	$-9.2M -127.2%	$33.7M

AI Insight: BTMD Financial Trends

Revenue declining steadily toward $45M while negative equity persists despite modest debt reduction.

• Revenue fell from $49M (Q2 2024) to $45M (Q1 2026), a 8% decline over eight quarters.

• Total debt decreased from $119M to $108M; equity improved from -$143M to -$56M, reducing liabilities.

• Operating income volatile, ranging $3M–$12M; net income erratic with three quarters of losses or near-break-even.

⚠ Operating cash flow halved from $16M (Q3 2024) to $4M (Q1 2026), signaling cash generation weakness.

⚠ Negative equity of -$56M persists despite debt reduction; balance sheet remains structurally impaired.

⚠ Revenue contraction accelerating; latest quarter $45M marks lowest in data series.

AI Insight: BTMD Ratio Trends

BTMD's profitability has collapsed across all metrics in Q1 2026, with operating margin falling to 7.0% and ROIC plummeting 29.2pp from Q4 2025.

• Operating margin declined from 14.7% (Q4 2025) to 7.0% (Q1 2026), lowest since Q4 2024's 5.5%.

• ROIC fell sharply from 53.7% (Q4 2025) to 24.5% (Q1 2026), first sub-30% reading in 3 quarters.

• Net profit margin compressed to 5.1% (Q1 2026) from 4.2% (Q4 2025), though above recent lows.

⚠ ROA deteriorated to 10.2% (Q1 2026) from 12.2% (Q2 2025)—consistent quarterly erosion warrants investigation into asset turnover or margins.

⚠ Extreme volatility in quarterly margins (5.5%–23.7% OpMargin) suggests operational instability or seasonal swings; sustainability unclear.

Get alerted when BTMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for biote Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BTMD

325 CAPITAL LLC
$6.1M4,548,127 sh
Bandera Partners LLC
$2.8M2,065,482 sh
BlackRock, Inc.
$2.3M1,739,244 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.5M1,113,855 sh
STATE STREET CORP
$873.4K646,954 sh
GEODE CAPITAL MANAGEMENT, LLC
$831.3K615,662 sh
DIMENSIONAL FUND ADVISORS LP
$733.6K543,494 sh
GLOBEFLEX CAPITAL L P
$367.7K272,400 sh
NORTHERN TRUST CORP
$363.3K269,113 sh
RENAISSANCE TECHNOLOGIES LLC
$359.0K265,916 sh

Fund	Value	Shares
325 CAPITAL LLC	$6.1M	4,548,127
Bandera Partners LLC	$2.8M	2,065,482
BlackRock, Inc.	$2.3M	1,739,244
VANGUARD CAPITAL MANAGEMENT LLC	$1.5M	1,113,855
STATE STREET CORP	$873.4K	646,954
GEODE CAPITAL MANAGEMENT, LLC	$831.3K	615,662
DIMENSIONAL FUND ADVISORS LP	$733.6K	543,494
GLOBEFLEX CAPITAL L P	$367.7K	272,400
NORTHERN TRUST CORP	$363.3K	269,113
RENAISSANCE TECHNOLOGIES LLC	$359.0K	265,916

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BTMD on your watchlist

Track score changes the day biote Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BTMD a good stock to buy?

13F Pro's AI-powered analysis of biote Corp. (BTMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BTMD are available on the BTMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BTMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BTMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of biote Corp.'s investment landscape.